Increased MALAT1 expression in tumor tissues of NSCLC patients is associated with an unfavorable overall survival [19], while the high expression of MALAT1 in tumor tissues was also found to be associated with an increased risk of metastasis and a poor overall survival among colorectal cancer [21], pancreatic cancer [22], glioma [23], and clear cell renal cell carcinoma [24]. This evidence concerns the gene MALAT1 and non-small cell lung carcinoma.